Lipid and apolipoprotein ratios: Association with coronary artery disease and effects of rosuvastatin compared wtih atorvastatin, pravastatin, and simvastatin

Plasma lipid and apolipoprotein ratios that include both an atherogenic and an antiatherogenic lipid component (eg, total cholesterol/high-density lipoprotein [HDL] cholesterol ratio, low-density lipoprotein [LDL] cholesterol/HDL cholesterol ratio, non-HDL cholesterol/HDL cholesterol ratio, and apol...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of cardiology Vol. 91; no. 5A; p. C20
Main Authors Rader, Daniel J, Davidson, Michael H, Caplan, RIchard J, Pears, John S
Format Journal Article
LanguageEnglish
Published New York Elsevier Limited 06.03.2003
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Plasma lipid and apolipoprotein ratios that include both an atherogenic and an antiatherogenic lipid component (eg, total cholesterol/high-density lipoprotein [HDL] cholesterol ratio, low-density lipoprotein [LDL] cholesterol/HDL cholesterol ratio, non-HDL cholesterol/HDL cholesterol ratio, and apolipoprotein [apo] B/apo A-I ratio) have been found to be strong predictors of coronary artery disease (CAD) risk. Three trials that compared the effects of rosuvastatin 10 mg versus atorvastatin 10 mg and 2 trials that compared the effects of rosuvastatin 10 mg versus simvastatin 20 mg and pravastatin 20 mg on lipid ratios in patients with hypercholesterolemia were prospectively designed for pooled analysis. At 12 weeks, in the 3-trial pooled analysis, rosuvastatin 10 mg (n = 389) showed significantly greater reductions in all 4 lipid ratios compared with atorvastatin 10 mg (n = 393) (p <0.001). The mean percent reduction from baseline in the LDL cholesterol/HDL cholesterol ratio was 51% in patients treated with rosuvastatin 10 mg versus 39% in patients treated with atorvastatin 10 mg. In the 2-trial pooled analysis, treatment with rosuvastatin 10 mg (n = 226) also resulted in significantly greater reductions in all 4 lipid ratios compared with both simvastatin 20 mg (n = 249) and pravastatin 20 mg (n = 252) (p <0.001). Mean percent reductions from baseline in the LDL cholesterol/HDL cholesterol ratio were 52%, 39%, and 30% for rosuvastatin 10 mg, simvastatin 20 mg, and pravastatin 20 mg, respectively, in these 2 trials. [PUBLICATION ABSTRACT]
AbstractList Plasma lipid and apolipoprotein ratios that include both an atherogenic and an antiatherogenic lipid component (eg, total cholesterol/high-density lipoprotein [HDL] cholesterol ratio, low-density lipoprotein [LDL] cholesterol/HDL cholesterol ratio, non-HDL cholesterol/HDL cholesterol ratio, and apolipoprotein [apo] B/apo A-I ratio) have been found to be strong predictors of coronary artery disease (CAD) risk. Three trials that compared the effects of rosuvastatin 10 mg versus atorvastatin 10 mg and 2 trials that compared the effects of rosuvastatin 10 mg versus simvastatin 20 mg and pravastatin 20 mg on lipid ratios in patients with hypercholesterolemia were prospectively designed for pooled analysis. At 12 weeks, in the 3-trial pooled analysis, rosuvastatin 10 mg (n = 389) showed significantly greater reductions in all 4 lipid ratios compared with atorvastatin 10 mg (n = 393) (p <0.001). The mean percent reduction from baseline in the LDL cholesterol/HDL cholesterol ratio was 51% in patients treated with rosuvastatin 10 mg versus 39% in patients treated with atorvastatin 10 mg. In the 2-trial pooled analysis, treatment with rosuvastatin 10 mg (n = 226) also resulted in significantly greater reductions in all 4 lipid ratios compared with both simvastatin 20 mg (n = 249) and pravastatin 20 mg (n = 252) (p <0.001). Mean percent reductions from baseline in the LDL cholesterol/HDL cholesterol ratio were 52%, 39%, and 30% for rosuvastatin 10 mg, simvastatin 20 mg, and pravastatin 20 mg, respectively, in these 2 trials. [PUBLICATION ABSTRACT]
Author Davidson, Michael H
Caplan, RIchard J
Rader, Daniel J
Pears, John S
Author_xml – sequence: 1
  givenname: Daniel
  surname: Rader
  middlename: J
  fullname: Rader, Daniel J
– sequence: 2
  givenname: Michael
  surname: Davidson
  middlename: H
  fullname: Davidson, Michael H
– sequence: 3
  givenname: RIchard
  surname: Caplan
  middlename: J
  fullname: Caplan, RIchard J
– sequence: 4
  givenname: John
  surname: Pears
  middlename: S
  fullname: Pears, John S
BookMark eNqNjkFLA0EMhQep4Fb9D8GzCzu7ah1vIooHj72XsJulKe1kTGYt_hl_q1OxePUQHl9e3iNzN4sS6cRV_n4Rah98N3NV0zRtHfxNOHNzs01B72_vKvf1xokHwFgmyZaTJJVMHEExs9gDPJpJzweIsOe8hl5UIuonoGYqMrARGv100DhSnw1kBBWbPtByScaS2SVUGmCfeQ2YRY_WNSTFPziUGO-Oiwt3OuLW6PJXz93Vy_Py6bUuX75PZHm1kUljsVZt13SLtgmh-9fRN_2SYHA
CODEN AJCDAG
ContentType Journal Article
Copyright Copyright Elsevier Sequoia S.A. Mar 6, 2003
Copyright_xml – notice: Copyright Elsevier Sequoia S.A. Mar 6, 2003
DBID 7TS
8FD
FR3
K9.
M7Z
NAPCQ
P64
DatabaseName Physical Education Index
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biochemistry Abstracts 1
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
DatabaseTitle Nursing & Allied Health Premium
Technology Research Database
Biochemistry Abstracts 1
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Physical Education Index
Biotechnology and BioEngineering Abstracts
DatabaseTitleList Nursing & Allied Health Premium
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1879-1913
ExternalDocumentID 325253951
GroupedDBID ---
--K
--M
.55
.GJ
.~1
0R~
123
1B1
1RT
1~.
1~5
23M
3O-
4.4
457
4G.
53G
5RE
5VS
6J9
7-5
71M
7RV
7TS
8FD
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAQFI
AAQQT
AAWTL
AAXKI
AAXUO
AAYOK
ABBQC
ABFNM
ABLJU
ABMAC
ABOCM
ABPPZ
ABXDB
ACDAQ
ACGFO
ACIUM
ACIWK
ACPRK
ACRLP
ADBBV
ADEZE
ADFRT
ADMUD
ADUKH
AEKER
AENEX
AFCTW
AFFNX
AFKRA
AFKWA
AFRAH
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AHHHB
AHMBA
AIEXJ
AIKHN
AITUG
AJOXV
AJRQY
AKRWK
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
AXJTR
BENPR
BKOJK
BKOMP
BLXMC
BNPGV
CS3
EBS
EFJIC
EJD
EO9
EP2
EP3
EX3
F5P
FDB
FIRID
FNPLU
FR3
FYGXN
G-Q
HZ~
IH2
IHE
J1W
J5H
K-O
K9.
KOM
L7B
M1P
M29
M2O
M41
M7Z
MO0
N9A
NAPCQ
O-L
O9-
OAUVE
OHT
OZT
P-9
P2P
P64
PC.
PQQKQ
Q38
RIG
ROL
RPZ
SDF
SDG
SEL
SES
SJN
SPCBC
SSH
SSZ
T5K
TWZ
UNMZH
UV1
WH7
WOW
X7M
XPP
YFH
YOC
YYP
YZZ
ZGI
~G-
ID FETCH-proquest_journals_2303720993
ISSN 0002-9149
IngestDate Fri Sep 13 09:39:59 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 5A
Language English
LinkModel OpenURL
MergedId FETCHMERGED-proquest_journals_2303720993
PQID 230372099
PQPubID 41200
ParticipantIDs proquest_journals_230372099
PublicationCentury 2000
PublicationDate 20030306
PublicationDateYYYYMMDD 2003-03-06
PublicationDate_xml – month: 03
  year: 2003
  text: 20030306
  day: 06
PublicationDecade 2000
PublicationPlace New York
PublicationPlace_xml – name: New York
PublicationTitle The American journal of cardiology
PublicationYear 2003
Publisher Elsevier Limited
Publisher_xml – name: Elsevier Limited
SSID ssj0001156
Score 3.455831
Snippet Plasma lipid and apolipoprotein ratios that include both an atherogenic and an antiatherogenic lipid component (eg, total cholesterol/high-density lipoprotein...
SourceID proquest
SourceType Aggregation Database
StartPage C20
SubjectTerms Cardiovascular disease
Drug therapy
Lipids
Title Lipid and apolipoprotein ratios: Association with coronary artery disease and effects of rosuvastatin compared wtih atorvastatin, pravastatin, and simvastatin
URI https://www.proquest.com/docview/230372099/abstract/
Volume 91
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LSsNAFB1qF-JGfKJWZRB3NiWP5lF3pbRU0QqSQnchL7GgSUlTQRd-it_ip3nn5UyoFHUTmhkypLmHO_feOWcGoXOTTLte6GpObKeQoHiG5oW2q8VJaEa2p4N7oCzfkTMct68n9qRW-1RYS4syasVvP-pK_mNVaAO7EpXsHyz7PSg0wG-wL1zBwnD9lY3JwdMJ226VHLYwy-muC0ShQr43Jbspn1_QzIucSnApmfNVrNDQURRyB0yei5eQyI0qRPVy-nhB0nTRRSw0K0L1llbip8-iSY1-fSljydQ9K2JKilXr-_dhwrDEJPBy8Ypy8OcVyr_UV_TC2RNf17qicjL5HLj-Yi64x7zeK4odFmV7ObICJ1Q4y-ov4tk7Btv-tJUyZ-65HQ3yUUv19uxsMI5qu6v47p6py0lREAFGd8FgfHMT-P2JX-1lMYBpm7bVIRr-NcsglNLWu6QYQbTtiPSLvNvSfE-DGH8LbfLsA3cZlLZRLc120Pot51fsog-KKAwmxFVEYYaoS6zgCRM8YYEnzPCEOZ7oGBxPOH_AKp6wwBMmeMIqnppYQVOTDqJgaQ-dDfp-b6iJ_xdwEM0DyHHJSUgQB--jepZn6QHCsRlDGGvokRGZ7dA1Iidy2rGnJxFML-A8DlFjxUBHK3sbaEMi5xjVy2KRnkDgWEan1DpfbP2DaA
link.rule.ids 315,786,790
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lipid+and+apolipoprotein+ratios%3A+Association+with+coronary+artery+disease+and+effects+of+rosuvastatin+compared+wtih+atorvastatin%2C+pravastatin%2C+and+simvastatin&rft.jtitle=The+American+journal+of+cardiology&rft.au=Rader%2C+Daniel+J&rft.au=Davidson%2C+Michael+H&rft.au=Caplan%2C+RIchard+J&rft.au=Pears%2C+John+S&rft.date=2003-03-06&rft.pub=Elsevier+Limited&rft.issn=0002-9149&rft.eissn=1879-1913&rft.volume=91&rft.issue=5A&rft.spage=C20&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=325253951
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-9149&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-9149&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-9149&client=summon